Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Meletios Α. Dimopoulos, Efstathios Kastritis, Roger G. Owen, et al.
Blood (2014) Vol. 124, Iss. 9, pp. 1404-1411
Open Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
Steven P. Treon, Christina Tripsas, Kirsten Meid, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 15, pp. 1430-1440
Open Access | Times Cited: 860
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Constantine S. Tam, Stephen Opat, Shirley D’Sa, et al.
Blood (2020) Vol. 136, Iss. 18, pp. 2038-2050
Open Access | Times Cited: 368
Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Anna Sureda, Peter Bader, Simone Cesaro, et al.
Bone Marrow Transplantation (2015) Vol. 50, Iss. 8, pp. 1037-1056
Closed Access | Times Cited: 321
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Meletios Α. Dimopoulos, Alessandra Tedeschi, Judith Trotman, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 25, pp. 2399-2410
Open Access | Times Cited: 316
Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Rafael F. Duarte, Myriam Labopin, Peter Bader, et al.
Bone Marrow Transplantation (2019) Vol. 54, Iss. 10, pp. 1525-1552
Open Access | Times Cited: 288
How I treat Waldenström macroglobulinemia
Steven P. Treon
Blood (2015) Vol. 126, Iss. 6, pp. 721-732
Open Access | Times Cited: 283
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
John A. Snowden, Isabel Sánchez‐Ortega, Selim Corbacioglu, et al.
Bone Marrow Transplantation (2022) Vol. 57, Iss. 8, pp. 1217-1239
Open Access | Times Cited: 258
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
The Lancet Oncology (2016) Vol. 18, Iss. 2, pp. 241-250
Closed Access | Times Cited: 227
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
Jorge J. Castillo, Ranjana H. Advani, Andrew R. Branagan, et al.
The Lancet Haematology (2020) Vol. 7, Iss. 11, pp. e827-e837
Closed Access | Times Cited: 125
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial
Sigbjørn Berentsen, Ulla Randen, Markku Oksman, et al.
Blood (2017) Vol. 130, Iss. 4, pp. 537-541
Open Access | Times Cited: 113
Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
Stéphanie Poulain, Christophe Roumier, Aurélie Venet-Caillault, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 6, pp. 1480-1488
Open Access | Times Cited: 110
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing
Steven H. Swerdlow, Işınsu Kuzu, Ahmet Doğan, et al.
Virchows Archiv (2015) Vol. 468, Iss. 3, pp. 259-275
Open Access | Times Cited: 108
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
Maria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.
Leukemia (2018) Vol. 32, Iss. 9, pp. 1883-1898
Open Access | Times Cited: 97
Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia
Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Prashant Kapoor, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 16, pp. 1403-1411
Open Access | Times Cited: 80
A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia
Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, et al.
Cancer Science (2020) Vol. 111, Iss. 9, pp. 3327-3337
Open Access | Times Cited: 72
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management
Morie A. Gertz
American Journal of Hematology (2020) Vol. 96, Iss. 2, pp. 258-269
Open Access | Times Cited: 71
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline
Guy Pratt, Dima El‐Sharkawi, Jaimal Kothari, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 2, pp. 171-187
Closed Access | Times Cited: 39
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes
Josephine M.I. Vos, Joshua Gustine, Helmut G. Rennke, et al.
British Journal of Haematology (2016) Vol. 175, Iss. 4, pp. 623-630
Open Access | Times Cited: 85
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Stéphanie Poulain, Christophe Roumier, Elisabeth Bertrand, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 20, pp. 6325-6335
Open Access | Times Cited: 80
Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management
Morie A. Gertz
American Journal of Hematology (2018) Vol. 94, Iss. 2, pp. 266-276
Open Access | Times Cited: 75
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
Maria Gavriatopoulou, Ramón García‐Sánz, Efstathios Kastritis, et al.
Blood (2016) Vol. 129, Iss. 4, pp. 456-459
Open Access | Times Cited: 72
Investigation and management of IgM and Waldenström‐associated peripheral neuropathies: recommendations from the IWWM‐8 consensus panel
Shirley D’Sa, Marie José Kersten, Jorge J. Castillo, et al.
British Journal of Haematology (2017) Vol. 176, Iss. 5, pp. 728-742
Open Access | Times Cited: 69
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
Meletios Α. Dimopoulos, Ramón García‐Sánz, Hui‐Peng Lee, et al.
Blood Advances (2020) Vol. 4, Iss. 23, pp. 6009-6018
Open Access | Times Cited: 66
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Christian Buske, Jorge J. Castillo, Jithma P. Abeykoon, et al.
Seminars in Hematology (2023) Vol. 60, Iss. 2, pp. 73-79
Open Access | Times Cited: 17
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells
Kasyapa S. Chitta, Aneel Paulus, Sharoon Akhtar, et al.
British Journal of Haematology (2015) Vol. 169, Iss. 3, pp. 377-390
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top